Capstone Asset Management Co. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 11.1% during the second quarter, according to its most recent filing with the SEC. The firm owned 80,080 shares of the company’s stock after selling 9,965 shares during the period. Capstone Asset Management Co.’s holdings in Johnson & Johnson were worth $10,594,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Lenox Wealth Advisors Inc. grew its holdings in shares of Johnson & Johnson by 0.7% during the 1st quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock worth $108,000 after acquiring an additional 6 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its holdings in shares of Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after acquiring an additional 841 shares during the period. Ullmann Financial Group Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $186,000. Taylor Wealth Management Partners grew its holdings in shares of Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after acquiring an additional 250 shares during the period. Finally, Foundation Resource Management Inc. purchased a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $204,000. Hedge funds and other institutional investors own 65.90% of the company’s stock.

Johnson & Johnson (NYSE JNJ) traded down 0.27% during trading on Friday, reaching $131.39. The company had a trading volume of 4,334,862 shares. The stock has a 50 day moving average of $132.79 and a 200-day moving average of $129.43. The stock has a market capitalization of $352.65 billion, a P/E ratio of 22.23 and a beta of 0.79. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. During the same period in the previous year, the company earned $1.74 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. On average, analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.56%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now directly owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.

JNJ has been the topic of a number of research analyst reports. UBS AG reiterated a “buy” rating and set a $148.00 target price (up previously from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Alembic Global Advisors downgraded Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. BMO Capital Markets reiterated a “buy” rating and set a $145.00 target price on shares of Johnson & Johnson in a report on Friday, September 1st. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Finally, Morgan Stanley boosted their price target on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 5th. Five research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $135.29.

TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Shares Sold by Capstone Asset Management Co.” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/24/johnson-johnson-jnj-shares-sold-by-capstone-asset-management-co.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.